Back

The Drug-Induced Cardiotoxicity Website and App

XV.e

XV - Chest pain

Pleuritis (can cause chest pain)

Last update 06/02/2022

See also undrer XIc. Can be with acute onset and marked symptoms in the form of acute chest pain. Generally with basilar infiltrates and blunting of costophrenic angles. Discrepancy between the acute chest symptoms and minimal changes on imaging. Tends to relapse if patient rechallenged with the drug. A.k.a. 'acute pleuro-pulmonary reaction'.

Causative drugs

6

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

Atezolizumab
XXXVI.ac
Dasatinib
X.d
XI.a
XII.b
XII.n
XIV.a
XIV.h
XIV.n
XXIV.j
XXIV.ad
XXX.w
XXX.x
Gemcitabine
II.l
VI.a
X.b
X.f
XI.i
XVI.j
XXII.b
XXIV.d
XXIV.f
XXIV.n
XXIV.w
XXIX.j
XXX.l
XXX.ab
XXXIII.k
XXXIV.g
XXXVI.q
Hydralazine
XII.e
XII.g
XVI.e
XVI.g
XX.c
XX.d
XXVIII.a
XXVIII.d
XXIX.b
XXXVI.a
XXXVI.b
XXXVI.s
XXXVI.t
XXXVI.u
XXXVIII.a
XXXVIII.c
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
I.a
I.c
I.d
II.a
II.m
III.a
IV.a
V.a
V.e
VI.c
VII.a
X.a
XIII.a
XIV.i
XVI.h
XXI.a
XXIV.e
XXIV.m
XXIV.p
XXIV.r
XXIV.ac
XXIV.ae
XXIX.i
XXX.h
XXXIII.f
XXXVI.v
Nitrofurantoin
II.n
XIV.d
XV.a
XV.b
XV.e
XVI.c
XXIV.a
XXIV.b
XXIV.c
XXIV.h
XXIV.k
XXIV.ai
XXV.i
XXVIII.o
XXIX.a
XXX.u
XXX.z
XXXVI.f
XXXVI.m